Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Margolin

Showing results (301-310 of 406) with videos related to

Pageof 41
Sort By:
Annals of Internal Medicine|April 1, 1988
Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trialR I Fisher, C A Coltman, J H Doroshow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1994
Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanomaM B Atkins, K R O'Boyle, J A Sosman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1989
Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelinesK A Margolin, A A Rayner, M J Hawkins, et al.
Cancer Research|May 1, 1992
Pharmacokinetics and toxicity of continuous infusion (6S)-folinic acid and bolus 5-fluorouracil in patients with advanced cancerE M Newman, S A Akman, J S Harrison, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 7, 2012
Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotypeAude G Chapuis, John A Thompson, Kim A Margolin, et al.
Journal of the American College of Surgeons|December 3, 2014
Perfusion assessment in laparoscopic left-sided/anterior resection (PILLAR II): a multi-institutional studyMehraneh D Jafari, Steven D Wexner, Joseph E Martz, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 22, 2011
NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapyGary R Hudes, Michael A Carducci, Toni K Choueiri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 1998
Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group studyK A Margolin, P Y Liu, L E Flaherty, et al.
Cancer Cell|October 10, 2018
Complement C5a Fosters Squamous Carcinogenesis and Limits T Cell Response to ChemotherapyTerry R Medler, Dhaarini Murugan, Wesley Horton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1990
Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II studyD R Parkinson, J S Abrams, P H Wiernik, et al.
Pageof 41

Showing results (301-310 of 406) with videos related to

Sort By:
Pageof 41
Annals of Internal Medicine|April 1, 1988
Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trialR I Fisher, C A Coltman, J H Doroshow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1994
Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanomaM B Atkins, K R O'Boyle, J A Sosman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1989
Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelinesK A Margolin, A A Rayner, M J Hawkins, et al.
Cancer Research|May 1, 1992
Pharmacokinetics and toxicity of continuous infusion (6S)-folinic acid and bolus 5-fluorouracil in patients with advanced cancerE M Newman, S A Akman, J S Harrison, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 7, 2012
Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotypeAude G Chapuis, John A Thompson, Kim A Margolin, et al.
Journal of the American College of Surgeons|December 3, 2014
Perfusion assessment in laparoscopic left-sided/anterior resection (PILLAR II): a multi-institutional studyMehraneh D Jafari, Steven D Wexner, Joseph E Martz, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 22, 2011
NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapyGary R Hudes, Michael A Carducci, Toni K Choueiri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 1998
Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group studyK A Margolin, P Y Liu, L E Flaherty, et al.
Cancer Cell|October 10, 2018
Complement C5a Fosters Squamous Carcinogenesis and Limits T Cell Response to ChemotherapyTerry R Medler, Dhaarini Murugan, Wesley Horton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1990
Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II studyD R Parkinson, J S Abrams, P H Wiernik, et al.
Pageof 41